Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10506)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
RAF1
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4) [Suppressor]
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
| Responsed Drug | Tetraarsenic tetrasulfide | Investigative | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| MAPK signaling pathway | hsa04010 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
In Vitro Model |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 |
| A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
| H1650-ER1 cells | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_4V01 | |
| Response regulation | On H23 cells treated with realgar, the expression of GPX4, SCL7A11 decreased while ACSL4 expression increased; this effect could also be amplified by Sorafenib. In conclusion, the present study indicated that realgar may induce ferroptosis by regulating the Raf, and hence plays a role in antiKRAS mutant lung cancer. | |||
Long-chain-fatty-acid--CoA ligase 4 (ACSL4) [Driver]
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
| Target for Ferroptosis | Driver | |||
| Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
| Responsed Drug | Tetraarsenic tetrasulfide | Investigative | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| MAPK signaling pathway | hsa04010 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
In Vitro Model |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 |
| A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
| H1650-ER1 cells | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_4V01 | |
| Response regulation | On H23 cells treated with realgar, the expression of GPX4, SCL7A11 decreased while ACSL4 expression increased; this effect could also be amplified by Sorafenib. In conclusion, the present study indicated that realgar may induce ferroptosis by regulating the Raf, and hence plays a role in antiKRAS mutant lung cancer. | |||
Cystine/glutamate transporter (SLC7A11) [Driver; Suppressor]
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
| Responsed Drug | Tetraarsenic tetrasulfide | Investigative | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| MAPK signaling pathway | hsa04010 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
In Vitro Model |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 |
| A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
| H1650-ER1 cells | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_4V01 | |
| Response regulation | On H23 cells treated with realgar, the expression of GPX4, SCL7A11 decreased while ACSL4 expression increased; this effect could also be amplified by Sorafenib. In conclusion, the present study indicated that realgar may induce ferroptosis by regulating the Raf, and hence plays a role in antiKRAS mutant lung cancer. | |||
Lung cancer [ICD-11: 2C25]
| In total 3 item(s) under this disease | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
| Target Regulator | RAF proto-oncogene serine/threonine-protein kinase (RAF1) | Protein coding | ||
| Responsed Drug | Tetraarsenic tetrasulfide | Investigative | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| MAPK signaling pathway | hsa04010 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
In Vitro Model |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 |
| A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
| H1650-ER1 cells | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_4V01 | |
| Response regulation | On H23 cells treated with realgar, the expression of GPX4, SCL7A11 decreased while ACSL4 expression increased; this effect could also be amplified by Sorafenib. In conclusion, the present study indicated that realgar may induce ferroptosis by regulating the Raf, and hence plays a role in antiKRAS mutant lung cancer. | |||
| Experiment 2 Reporting the Ferroptosis-centered Disease Response | [1] | |||
| Target Regulator | RAF proto-oncogene serine/threonine-protein kinase (RAF1) | Protein coding | ||
| Responsed Drug | Tetraarsenic tetrasulfide | Investigative | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| MAPK signaling pathway | hsa04010 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
In Vitro Model |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 |
| A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
| H1650-ER1 cells | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_4V01 | |
| Response regulation | On H23 cells treated with realgar, the expression of GPX4, SCL7A11 decreased while ACSL4 expression increased; this effect could also be amplified by Sorafenib. In conclusion, the present study indicated that realgar may induce ferroptosis by regulating the Raf, and hence plays a role in antiKRAS mutant lung cancer. | |||
| Experiment 3 Reporting the Ferroptosis-centered Disease Response | [1] | |||
| Target Regulator | RAF proto-oncogene serine/threonine-protein kinase (RAF1) | Protein coding | ||
| Responsed Drug | Tetraarsenic tetrasulfide | Investigative | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| MAPK signaling pathway | hsa04010 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
In Vitro Model |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 |
| A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
| H1650-ER1 cells | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_4V01 | |
| Response regulation | On H23 cells treated with realgar, the expression of GPX4, SCL7A11 decreased while ACSL4 expression increased; this effect could also be amplified by Sorafenib. In conclusion, the present study indicated that realgar may induce ferroptosis by regulating the Raf, and hence plays a role in antiKRAS mutant lung cancer. | |||
Tetraarsenic tetrasulfide
[Investigative]
| In total 3 item(s) under this drug | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | |||
| Drug for Ferroptosis | Inducer | |||
| Response Target | Phospholipid hydroperoxide glutathione peroxidase (GPX4) | Suppressor | ||
| Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| MAPK signaling pathway | hsa04010 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
In Vitro Model |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 |
| A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
| H1650-ER1 cells | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_4V01 | |
| Response regulation | On H23 cells treated with realgar, the expression of GPX4, SCL7A11 decreased while ACSL4 expression increased; this effect could also be amplified by Sorafenib. In conclusion, the present study indicated that realgar may induce ferroptosis by regulating the Raf, and hence plays a role in antiKRAS mutant lung cancer. | |||
| Experiment 2 Reporting the Ferroptosis-centered Drug Response | [1] | |||
| Drug for Ferroptosis | Inducer | |||
| Response Target | Long-chain-fatty-acid--CoA ligase 4 (ACSL4) | Driver | ||
| Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| MAPK signaling pathway | hsa04010 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
In Vitro Model |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 |
| A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
| H1650-ER1 cells | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_4V01 | |
| Response regulation | On H23 cells treated with realgar, the expression of GPX4, SCL7A11 decreased while ACSL4 expression increased; this effect could also be amplified by Sorafenib. In conclusion, the present study indicated that realgar may induce ferroptosis by regulating the Raf, and hence plays a role in antiKRAS mutant lung cancer. | |||
| Experiment 3 Reporting the Ferroptosis-centered Drug Response | [1] | |||
| Drug for Ferroptosis | Inducer | |||
| Response Target | Cystine/glutamate transporter (SLC7A11) | Driver; Suppressor | ||
| Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| MAPK signaling pathway | hsa04010 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
In Vitro Model |
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 |
| A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | |
| H1650-ER1 cells | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_4V01 | |
| Response regulation | On H23 cells treated with realgar, the expression of GPX4, SCL7A11 decreased while ACSL4 expression increased; this effect could also be amplified by Sorafenib. In conclusion, the present study indicated that realgar may induce ferroptosis by regulating the Raf, and hence plays a role in antiKRAS mutant lung cancer. | |||
